PMI wants a partner to grow and operate Vectura's drug manufacturing outsourcing. Read More
Tags :Vectura
The firm's foray into pharma is proving more challenging than anticipated. Read More
The industry’s move into pharma may be positive for public health. Read More
Nearly half would consider switching inhalers, survey finds.Read More
The company's CEO and CFO have resigned following PMI’s controversial takeover. Read More
Respiratory societies tighten author restrictions after PMI's Vectura acquisition. Read More
The Drug Delivery to the Lungs conference has terminated Vectura’s sponsorship.Read More
The company has acquired or received valid acceptances for 74.77 percent shares in Vectura.Read More
The Vectura board has recommended PMI's 165 pence-per-share offer to shareholdersRead More
The inhaled drug manufacturer’s directors describe the bid as “fair and reasonable.”Read More